The ELEGANT trial enrolls all high-risk ER-positive patients, not just those with ESR1 mutations. The rationale is that unlike in metastatic disease, early breast cancer is fundamentally ER-driven. Elicestrin targets both wild-type and mutant ER, making the mutation status less critical for efficacy in this earlier setting.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

ESR1 mutations are rarely found in primary tumors but develop in metastatic settings under pressure from aromatase inhibitors, conferring resistance. This evolution necessitates serial, plasma-based genotyping upon each disease progression to identify these actionable mutations as they emerge.

The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.

Dr. Bardia emphasizes that ESR1 is an 'acquired alteration,' meaning the mutation can develop during treatment. This necessitates a shift from one-time diagnostic testing to a dynamic, serial testing model. Repeat testing is critical to identify these actionable mutations as they arise, allowing patients to access newly approved targeted therapies.

Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.

An ESR1 mutation locks the estrogen receptor in a permanently "on" state, independent of estrogen. This renders aromatase inhibitors (AIs) ineffective but means therapies that degrade the receptor itself, like SERDs, can still be effective treatment options.

In the EMBER-3 trial, the combination of the oral SERD imlunestrant and the CDK4/6 inhibitor abemaciclib showed a 41% reduction in progression risk versus the SERD alone. Critically, this benefit was observed regardless of the patient's ESR1 mutation status, indicating a broader mechanism of action.

The failure of the PERSEVERA trial, which tested a similar drug in an unselected patient population, highlights the critical importance of SERENA-6's biomarker-driven approach. It proves that targeting only patients with the ESR1 mutation is necessary for efficacy, reinforcing the core value of precision oncology.